Action plan for optimizing the design of clinical trials in chronic kidney disease

Vlado Perkovic, Jonathan Craig, Worawon Chailimpamontree, Caroline Fox, Guillermo Garcia-Garcia, Mohammed Gharbi, Meg Jardine, Ikechi Okpechi, Neesh Pannu, Benedicte Stengel, Katherine Tuttle, Katrin Uhlig, Andrew Levey

Research output: Contribution to journalReview articlepeer-review

7 Citations (Scopus)

Abstract

High-quality clinical trials are the cornerstone of evidence-based prevention and treatment of a disease, but nephrology has a strikingly weak base of such trials. Building the evidence base to improve outcomes for people with a kidney disease, therefore, requires both greater quantity and quality of clinical trials. To address these issues, we propose that we aim to enroll 30% of people with chronic kidney disease in trials by 2030. Goal 1: Strongly encourage and promote the conduct of clinical trials in people with chronic kidney disease to increase the number of clinical trials conducted. Goal 2: Optimize the design of clinical trials in people with chronic kidney disease. Goal 3: Increase the capacity for conducting clinical trials in people with chronic kidney disease.

Original languageEnglish
Pages (from-to)138-144
Number of pages7
JournalKidney International Supplements
Volume7
Issue number2
DOIs
Publication statusPublished - Oct 2017
Event2016 International Society of Nephrology Conference -
Duration: 1 Jul 2016 → …

Keywords

  • chronic kidney disease
  • clinical trial
  • clinical trial design
  • clinical trial endpoints

Fingerprint Dive into the research topics of 'Action plan for optimizing the design of clinical trials in chronic kidney disease'. Together they form a unique fingerprint.

Cite this